Gilead Sciences (XSWX:GILD) E10: CHF3.91 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XSWX:GILD Gilead Sciences Inc XSWX:GILD
69 GF Score
Price CHF106.02
GF Value CHF78.37
! 3 Warning Signs
View Full Analysis

What is Gilead Sciences E10?

Gilead Sciences XSWX:GILD -0.39% 69 E10 is CHF3.91 as of Mar. 2026. GuruFocus rates XSWX:GILD with a GF Score™ of 69/100 and a GF Value™ of CHF78.37. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Gilead Sciences's adjusted earnings per share data for the three months ended in Mar. 2026 was CHF1.268. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is CHF3.91 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Gilead Sciences's average E10 Growth Rate was -12.40% per year. During the past 3 years, the average E10 Growth Rate was -6.50% per year. During the past 5 years, the average E10 Growth Rate was 0.50% per year. During the past 10 years, the average E10 Growth Rate was 5.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of Gilead Sciences was 85.40% per year. The lowest was -6.50% per year. And the median was 17.80% per year.

As of today (2026-07-15), Gilead Sciences's current stock price is CHF106.02. Gilead Sciences's E10 for the quarter that ended in Mar. 2026 was CHF3.91. Gilead Sciences's Shiller PE Ratio of today is 27.12.

During the past 13 years, the highest Shiller PE Ratio of Gilead Sciences was 30.63. The lowest was 9.93. And the median was 13.75.


Gilead Sciences  (XSWX:GILD) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Gilead Sciences's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=106.02/3.91
=27.12

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Gilead Sciences was 30.63. The lowest was 9.93. And the median was 13.75.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Gilead Sciences E10 Related Terms


Gilead Sciences E10 Historical Data

* Premium members only.

The historical data trend for Gilead Sciences's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gilead Sciences E10 Chart

Gilead Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Gilead Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.91

XSWX:GILD vs PFE, AMGN, BMY: E10 Comparison

For the Drug Manufacturers - General subindustry, Gilead Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gilead Sciences Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Gilead Sciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Gilead Sciences's Shiller PE Ratio falls into.


XSWX:GILD
69GF Score
Gilead Sciences Inc XSWX:GILD
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Gilead Sciences E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Gilead Sciences's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=1.268/330.2130*330.2130
=1.268

Current CPI (Mar. 2026) = 330.2130.

Gilead Sciences Quarterly Data

per share eps CPI Adj_EPS
201606 2.501 241.018 3.427
201609 2.423 241.428 3.314
201612 2.385 241.432 3.262
201703 2.053 243.801 2.781
201706 2.256 244.955 3.041
201709 1.983 246.819 2.653
201712 -2.922 246.524 -3.914
201803 1.109 249.554 1.467
201806 1.376 251.989 1.803
201809 1.549 252.439 2.026
201812 0.002 251.233 0.003
201903 1.541 254.202 2.002
201906 1.452 256.143 1.872
201909 -0.911 256.759 -1.172
201912 2.083 256.974 2.677
202003 1.170 258.115 1.497
202006 -2.530 257.797 -3.241
202009 0.265 260.280 0.336
202012 1.093 260.474 1.386
202103 1.274 264.877 1.588
202106 1.098 271.696 1.334
202109 1.892 274.310 2.278
202112 0.276 278.802 0.327
202203 0.019 287.504 0.022
202206 0.883 296.311 0.984
202209 1.382 296.808 1.538
202212 1.211 296.797 1.347
202303 0.740 301.836 0.810
202306 0.747 305.109 0.808
202309 1.556 307.789 1.669
202312 0.986 306.746 1.061
202403 -2.968 312.332 -3.138
202406 1.153 314.175 1.212
202409 0.847 315.301 0.887
202412 1.266 315.605 1.325
202503 0.919 319.799 0.949
202506 1.269 322.561 1.299
202509 1.935 324.800 1.967
202512 1.387 324.054 1.413
202603 1.268 330.213 1.268

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of CHF3.91 mean?
Gilead Sciences (XSWX:GILD) has a E10 of CHF3.91 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Gilead Sciences and its competitors.
Is Gilead Sciences' E10 too high?
Gilead Sciences' current E10 is CHF3.91. Overall, Gilead Sciences has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Gilead Sciences' E10 compare to PFE and AMGN?
Gilead Sciences' E10 of CHF3.91 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Gilead Sciences and its competitors. Gilead Sciences's current E10 is CHF3.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gilead Sciences stock overvalued right now?
Gilead Sciences (XSWX:GILD) has a current E10 of CHF3.91. The stock's GF Value™ is CHF78.37, compared to a current price of CHF106.02 — trading 35.3% above its estimated fair value. The current E10 is CHF3.91. Gilead Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Gilead Sciences (XSWX:GILD), the current E10 is CHF3.91 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gilead Sciences (XSWX:GILD) Overvalued in 2026?

Based on GuruFocus' analysis, Gilead Sciences stock appears to be overvalued. The current stock price of CHF106.02 is trading 35.3% above its estimated GF Value™ of CHF78.37.

Key valuation signals for XSWX:GILD:

  • E10: CHF3.91
  • GF Value™: CHF78.37 vs. price of CHF106.02 (35.3% above fair value)
  • GF Score™: 69/100 with 3 warning signs

No single metric tells the full story. See the XSWX:GILD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gilead Sciences Business Description

Address 333 Lakeside Drive, Foster City, CA, USA, 94404
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
69GF Score

Get the complete analysis for XSWX:GILD

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF106.02
Price
CHF78.37
GF Value